Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Novo Nordisk A/S stock price
Today's ETR:NOVC chart, history & news
|Year to date change||14.23%|
About Novo Nordisk A/S
|Entity name||Report date||Shares held|
Aggregated insiders summary data for the last 6 months.
|Full name||Reported title||Total bought||Total sold||Net transacted|
|Full name||Reported title||Effective date||Amount of shares||Price per share||Total cost|
Novo Nordisk A/S dividends
|Ex date||Payment date||Record date||Declared date||Amount||Description||Frequency|
Novo Nordisk (ETR: NOVC) said on Thursday that its net profit in the fiscal second quarter came in stronger than what the experts had forecast. The company said that destocking and fewer new patients weighed on its performance in the recent quarter, but lower costs helped offset the pressure. Novo Nordisk achieved its target of using renewable electricity only, at its global production facilities earlier this week. Novo Nordisk’s stock bounced le...